Navigation Links
Experts Offer Tips on Lung Cancer Prevention
Date:9/11/2007

Supplements won't help lower risk, and neither will CT scans, guide says

MONDAY, Sept.10 (HealthDay News) -- People, especially smokers, should not rely on vitamin and mineral supplements to prevent lung cancer, say members of the American College of Chest Physicians in their second annual guide to lung cancer prevention, care and treatment.

The new evidence-based guidelines also include a strong statement opposing the use of low-dose CT scans for the general screening of lung cancer.

Lung cancer is the leading cause of cancer death in the United States. More people die from lung cancer than from colon, breast, prostate and pancreatic cancer combined.

"Each year, great strides are made in the diagnosis and treatment of lung cancer, allowing patients with the disease to live longer and increase the quality of their lives. However, the real culprit behind lung cancer is tobacco," Dr. Mark J. Rosen, president of the American College of Chest Physicians (ACCP), said in a prepared statement. "Avoiding tobacco is the key to preventing most forms of lung cancer. Until we eliminate tobacco use completely, we will continue to deal with its devastating health consequences."

Published as a supplement to the September issue of the college's journal Chest, the guidelines note there is little evidence to show lung cancer screening changes the outcome for patients, including those considered to be at high risk.

"Even in high-risk populations, currently available research data do not show that lung cancer screening alters mortality outcomes," Dr. W. Michael Alberts, chairman of the ACCP lung cancer guidelines, said in a prepared statement. "We hope that, one day, we can find a useful and accurate tool for general lung cancer screening but, at this time, the evidence does not support the use of LDCT screening."

This is the second edition of Diagnosis and Management of Lung Cancer: ACCP
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Smoking a greater risk than HIV? Yes say health experts!!!!
2. Good carb, bad carb? Experts debate.
3. Serevent, to be examined by experts due to deaths associated with its use
4. Spread Of Rocky Mountain Spotted Fever Is A Probability, Say Experts
5. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
6. Experts Insist That Neonatal Herpes Be Reported Regularly
7. Experts State Strategies To Increase Good Cholesterol
8. Speed up bird flu vaccine, Bush tells experts
9. Tennis elbow not new among cricketers, say experts
10. Cancer Can Recur Any Time, Experts Caution
11. Experts Building Bird Flu Warning System

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/8/2009)...aises House Passage of Health Care Reform Bill ,...e, improve coverage for all Americans ,, CHICA...nited States House of Representatives passed by a ...lation that would strengthen Medicare for seniors ... prices millions of Americans out of affordable he...
(Date:11/8/2009)...aises House Passage of Health Care Reform Bill ,...e, improve coverage for all Americans ,, BALTI... Tonight the United States House of Representative...hat would strengthen Medicare for seniors and end ...millions of Americans out of affordable health cov...
(Date:11/7/2009)...ON, Nov. 7 Karen Ignagn... Plans (AHIP), released the following statement to...lans strongly support comprehensive health care re...y proposing a complete overhaul of how health insu...guaranteed coverage, elimination of pre-existing c...
(Date:11/7/2009)... Nov. 7, The American M...njamin Rush Award for Citizenship and Community Se...from Chicago, IL. The award recognizes physicians ...call of duty to make an outstanding public service...received the award today during the opening sessio...
(Date:11/7/2009)...yn T. Coleman (CT), David A. Cook (GA), Louis J. G... (LA) Honored ,, CHICAGO, Nov. 7 /PRNewswire-U...A) today presented five medical society executive ...tributions to the goals and ideals of the medical ... semi-annual policy making meeting in Houston. ,...
Breaking Medicine News(10 mins):Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:AMA Honors Medical Society Executives 2
...he Prescription Drug User Fee Act (PDUFA) user fee...ry 18, 2008 -, YARDLEY, Pa., Sept. 20 Tibotec Ph...ug Application (NDA) for TMC125,(etravirine), an i...stration (FDA). The Prescription Drug User Fee,Act...
...LIN, N.J., Sept. 20 SyntheMed, Inc. (OTC,Bulletin...he development,and commercialization of anti-adhes...t the Circulatory System Devices Advisory Panel of...,likely to need secondary open heart surgery. The ...
...phyX(TM) receives FDA clearance, REDMOND, Wash., ... EsophyX(TM) device for performing Transoral Incis...ing gastroesophageal reflux,disease has received F...pleted yesterday under general anesthesia,transora...
...BOSTON Since the days of Hippocrates, people have ...seasons. More recently, researchers have learned t...seasonality, are often related to the weather. In ... Department of Public Heath and Family Medicine at...
...(Washington) Expressions of deep concern and disa...authorization will go forward without addressing s...for Medicare beneficiaries were sent today to cong...nal medicine physicians and medical student member...
...ndation Duped By Overseas Supplier, WAKEFIELD, Ma...tion established to support cancer-fighting resear...ng due to high lead levels the jewelry it,distribu... contain lead. When Friends of Mel recently learne...
Other Medicine News:Health News:FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125 2Health News:FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125 3Health News:FDA Panel Recommends Approval of SyntheMed's REPEL-CV(R) Adhesion Barrier for Pediatric Patients 2Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 2Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 3Health News:The First Incisionless Transoral Fundoplication for Treatment of Gastroesophageal Reflux is Performed in the U.S. at Ohio State University and Oregon Health & Science University Medical Centers 4Health News:Mathematics might save you a trip to the ER 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 3Health News:Friends of Mel Announce Recall of Jewelry Due to Lead 2Health News:Friends of Mel Announce Recall of Jewelry Due to Lead 3
(Date:11/6/2009)..., Nov. 6 Caraco Pharmace...aunched ketorolac tromethamine ophthalmic solution... and Drug Administration (FDA) for Sun Pharma,s Ab...Acular® opthalmic solution on the first day f...olac is therapeutically equivalent to Acular®...
(Date:11/6/2009)...IS, November 6 , - Trial ...lid for the,Treatment of Multi-Resistant Staphyloc... a speciality pharmaceutical company focused on th...esigned to overcome the significant global,problem... most advanced oral,antibacterial NXL103 (floprist...
(Date:11/5/2009)...GO, Nov. 5 Althea Technologies, I...turing services for biopharmaceutical products ann...lopment to the company,s platform of services, whi...es Matsuura, Director of Formulation Development. ...ion and analytical scientists, along with new labo...
Breaking Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Partnership to accelerate Trudeau Institute discoveries to patient care 8711 1Partnership to accelerate Trudeau Institute discoveries to patient care 8711 2Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 1Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 2Kidnapped Nonviolent Peaceforce Civilian Peacekeeper Released Unharmed 47816 3WWII Veterans Compete in National Veterans Golden Age Games 47813 1WWII Veterans Compete in National Veterans Golden Age Games 47813 2
...NTA, Dec. 11 The Arthritis Foundation,the leading...llion,Americans living with arthritis, today annou...eters of Enbrel (R) (etanercept), will be the,nati... (R)., "The Arthritis Foundation hosts hundreds o...to prevent, control and cure arthritis, the,nation...
...CETON, N.J. and FOSTER CITY, Calif., Dec. 11 /PRNe...(NYSE: BMY ) and Gilead Sciences, Inc.,(Nasdaq: ...ze ATRIPLA(R),(efavirenz 600 mg/emtricitabine 200 ... for the treatment of virologically suppressed adu... approval by the European,Commission. If approved,...
Other Medicine Technology:Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 2Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 3Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R) 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 2Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 5Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 6Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 7Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 8
Assay Development
Custom Conjugation
Iso-Electric Determination Kit
Rabbit Anti-Goat IgG (H & L) Antibody, Colloidal Gold Conjugated, 50 OD
Medicine Products: